212 related articles for article (PubMed ID: 33573708)
21. Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
Singh L; Pushker N; Sen S; Singh MK; Chauhan FA; Kashyap S
Clin Exp Ophthalmol; 2015 Aug; 43(6):550-7. PubMed ID: 25754767
[TBL] [Abstract][Full Text] [Related]
22. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
23. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
24. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
25. Targeted PLK1 suppression through RNA interference mediated by high-fidelity Cas13d mitigates osteosarcoma progression via TGF-β/Smad3 signalling.
Yuan Y; Cao D; Zhang A; Liu Z; Deng Z; Zhang S
J Cell Mol Med; 2024 May; 28(10):e18400. PubMed ID: 38780513
[TBL] [Abstract][Full Text] [Related]
26. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
[TBL] [Abstract][Full Text] [Related]
27. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
Lu J; Xin S; Meng H; Veldman M; Schoenfeld D; Che C; Yan R; Zhong H; Li S; Lin S
PLoS One; 2013; 8(4):e53317. PubMed ID: 23658603
[TBL] [Abstract][Full Text] [Related]
28. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
29. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
30. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
31. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
33. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
34. Lupeol induces autophagy and apoptosis with reduced cancer stem-like properties in retinoblastoma via phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin inhibition.
Che S; Wu S; Yu P
J Pharm Pharmacol; 2022 Feb; 74(2):208-215. PubMed ID: 33836050
[TBL] [Abstract][Full Text] [Related]
35. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
[TBL] [Abstract][Full Text] [Related]
36. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
[TBL] [Abstract][Full Text] [Related]
37. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
38. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
39. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
40. PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.
Gheghiani L; Wang L; Zhang Y; Moore XTR; Zhang J; Smith SC; Tian Y; Wang L; Turner K; Jackson-Cook CK; Mukhopadhyay ND; Fu Z
Cancer Res; 2021 Mar; 81(5):1293-1307. PubMed ID: 33376114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
